Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting

International Journal of Clinical Practice

Volumn 61, Issue 1, 2007, Pages 15-23

  Usher Smith, Juliet A ^a,e   Ramsbottom, T ^b   Pearmain, H ^c   Kirby, M ^d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Surgery   (United Kingdom)

^c North Hertfordshire and Stevenage Primary Care Trust   (United Kingdom)

^d UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CANDESARTAN; CHOLESTEROL; LOSARTAN; SIMVASTATIN;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; BLOOD PRESSURE; BRAIN INFARCTION; CHEST TIGHTNESS; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; COST CONTROL; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOTENSION; LACUNAR INFARCTION; MAJOR CLINICAL STUDY; MALE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; STROKE; VISUAL DISORDER;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUGS, GENERIC; FAMILY PRACTICE; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; PATIENT SATISFACTION; PYRROLES; SIMVASTATIN; TETRAZOLES; TREATMENT OUTCOME;

EID: 33847028362     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01217.x     Document Type: Article

References (16)

1. Furberg CD, Psaty BM. Should evidence-based proof of drug efficacy be extrapolated to a 'class of agents'? Circulation 2003; 108: 2608-10.
2. Antman EM, Ferguson JJ. Should evidence-based proof of efficacy as defined for a specific therapeutic agent be extrapolated to encompass a therapeutic class of agents? Circulation 2003; 108: 2604-7.
3. Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiol 1998; 81: 582-7.
4. Nishimura T, Hashimoto J, Ohkubo T et al. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements. Clin Exp Hypertens 2005; 6: 477- 89.
5. Lacourciere Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients. Am J Hypertens 1999; 12: 1181-7.
6. Baguet J-P, Nisse-Durgeat S, Mouret S et al. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring. Int J Clin Pract 2006; 60: 391-8.
7. Conlin PR. Angiotensin II antagonists in the treatment of hypertension: more similarities than differences. J Clin Hypertens 2000; 2: 253-7.
8. Raal FJ. A single-centre retrospective observational study to evaluate the change in total cholesterol and LDL cholesterol in hyperlipidaemic patients switched from atorvastatin to simvastatin. Cardiovasc J South Afr 2004; 15: 118-23.
9. Jones P, Davidson M, Stein E et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92: 152-60.
10. Heart Protection Study Collaborative Group. MCR/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
11. Moon JC. Switching statins. BMJ 2006; 332: 1344-5.
12. NHS Employers. New GMS Contract: Investing in General Practice. Available at: http://www.nhsemployers.org/primary/primary-902. cfm, accessed on 5 September 2006.
13. Lucini D, Di Fede G, Parati G et al. Impact of chronic psychosocial stress on autonomic cardiovascular regulation in otherwise healthy subjects. Hypertension 2005; 46: 1201-6.
14. Schmitt F, Natov S, Martinez F et al. Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man. Clin Sci 1996; 90: 205-13.
15. Rayner BL, Trinder YA, Baines D et al. Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics. Am J Hypertens 2006; 19: 208-13.
16. Thompson A, Green S, Dubois S et al. Evaluation of patient satisfaction with switching medication. Prescriber 2006; 17: 27-35.